Catalyst
Slingshot members are tracking this event:
FDA approves AstraZeneca's(AZN) Tagrisso as 1st-line treatment for EGFR-mutated non-small cell lung cancer
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| AZN |
|
|
||||
Additional Information
Tagrisso delivered unprecedented median progression-free survival of 18.9 months versus 10.2 months compared with current standard of care
Slingshot Insights Explained
Catalyst Date
Occurred on:
Apr 18, 2018
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Tagrisso, Egfr Mutation, Non-small Cell Lung Cancer
